BTIG Downgrades Zimmer Biomet, Cuts $112 Target Citing Low 1–3% Growth
BTIG downgraded Zimmer Biomet from Buy to Neutral and withdrew its $112 price target, citing eight quarters of 1–3% organic revenue growth and weak reception to 22 product launches. It flagged Paragon 28’s performance, a 10.5× forward earnings multiple below peers and near-term disruption from a U.S. salesforce direct-model shift.
1. Brokerage Downgrade Details
BTIG downgraded Zimmer Biomet from Buy to Neutral and withdrew its $112 price target, citing limited near-term catalysts to drive shares higher. The firm emphasized slowing growth momentum despite ongoing operational initiatives.
2. Revenue Growth Trends
Zimmer Biomet’s organic revenue growth has decelerated over eight consecutive quarters and is forecast to remain in the 1%–3% range for 2026, aligning with company guidance. This persistent slowdown is viewed as already reflected in the current valuation.
3. Product Launch Performance
The company introduced 22 new products in 2025 and plans eight more for 2026, but these launches have delivered average market reception and failed to boost top-line growth significantly. Additionally, Paragon 28, acquired in 2025, has underperformed expectations and is projected to contribute less in 2026.
4. Operational and Valuation Outlook
Zimmer Biomet trades at roughly 10.5× forward earnings, below peer multiples, constraining upside potential. The transition to a direct U.S. salesforce model through 2027 may cause near-term disruption, and investments in autonomous robotics are unlikely to materialize commercially until late 2027 or early 2028.